Screening for autoimmune type 1 diabetes (T1D)

How early can autoimmune type 1 diabetes be detected?


Autoimmune type 1 diabetes (T1D) is a lifelong condition with a progressive nature, 1 which is often diagnosed only after ​​symptoms appear. 2 Many people, especially children under 18 years old, find out about their condition only after a medical emergency. 2–4


Nowadays, screening tests exist that allow us to catch autoimmune type 1 diabetes early, even before symptoms appear, providing the opportunity to reduce the likelihood of starting the journey with a medical emergency and prepare for life with the condition.2,4-5 This proactive approach empowers people and gives them time to get informed on what autoimmune type 1 diabetes means for them.

What is autoimmune type 1 diabetes screening?


Autoimmune type 1 diabetes develops over time when the body’s immune system mistakenly attacks the insulin-producing cells of the pancreas (beta cells).1 A type of molecule produced by the immune system, called autoantibodies, is involved in this attack; autoantibodies appear months or years before the symptoms of the disease.5,6


Learn more about ​how autoimmune type 1 diabetes works in the body.


Screening for autoimmune type 1 diabetes can be done with a blood test, usually from a vein in the arm or from a fingertip, that identifies these autoantibodies.2,6,7 This is different from a blood glucose level test..


When a person has one type 1 diabetes autoantibody in the blood, it means there is a higher risk of developing autoimmune type 1 diabetes in the future.8 If two or more different type 1 diabetes autoantibodies are found in the blood, and the result is confirmed, then autoimmune type 1 diabetes has been detected.8

What autoantibodies are present in autoimmune type 1 diabetes?

Autoimmune type 1 diabetes screening will check the presence of four different type 1 diabetes autoantibodies in the blood.6,9 These autoantibodies can be found in the blood in different combinations.6,8

Who should get autoimmune type 1 diabetes screening?


For a long time, autoimmune type 1 diabetes has been considered a childhood condition.10,11 Now it is known that anyone at any age can get autoimmune type 1 diabetes, although people younger than 35 years are more likely to develop this condition.9,10


Many factors may increase the likelihood of getting autoimmune type 1 diabetes, for example:

  • Having a relative with autoimmune type 1 diabetes
  • Having a personal or family history of other autoimmune conditions, such as celiac or thyroid disease. 9,15


People with a parent or a sibling with autoimmune type 1 diabetes are recommended to get an autoantibody screening for type 1 diabetes, since they have an up to 15 times higher chance (15-fold) of developing this condition than others.2,8,13


However, most people with autoimmune type 1 diabetes do not have any family history; this means that anyone can develop the condition, and it is more often detected in people who have low body mass index and are younger than 35.9,13


Type 1 diabetes autoantibodies usually appear between 9 months and 2 years of age.9 Screening for autoimmune type 1 diabetes should ideally be done early in life, initially at 2 years of age and then at 6 years of age, to improve the chance of early detection.14


Sometimes, prediabetes (a condition with blood glucose levels slightly higher than usual) and type 2 diabetes can look similar to autoimmune type 1 diabetes, even though they’re not autoimmune conditions. Screening for autoantibodies can therefore be helpful to distinguish autoimmune type 1 diabetes from type 2.8,9


Learn more about the ​misdiagnosis of autoimmune type 1 diabetes.

How to get autoimmune type 1 diabetes screening?


Different autoimmune type 1 diabetes screening programs can be available in different areas.2,9 Depending on where you live, your or your child’s doctor can order labs to detect type 1 diabetes autoantibodies, and your insurance may cover this. Your child’s doctor will recommend the best autoimmune T1D screening option for you among those available.


If type 1 diabetes autoantibodies are found in the first screening test, the test should be repeated 3 months later to confirm the result.8 If type 1 diabetes autoantibodies are not found in the second test, it is important that you monitor the appearance of potential autoimmune type 1 diabetes symptoms.8,12

What do the results of type 1 diabetes autoantibody screening mean?


The screening test can give different results, each one suggesting a different course of action:


  • If no autoantibodies are detected, autoimmune type 1 diabetes has not been detected. Repeat screening may be recommended for individuals at higher risk of developing the condition, such as those with other autoimmune conditions or a close family member (parent or sibling) with autoimmune type 1 diabetes. 15
  • If one autoantibody is detected, it means there is a higher risk of developing autoimmune type 1 diabetes. Monitoring and additional screening may be recommended to see if there are any changes.8
  • If two or more autoantibodies for type 1 diabetes are detected and the result is confirmed, then autoimmune type 1 diabetes has been detected. Further testing of blood sugar levels may be recommended to understand how the condition is progressing and at what stage you are.16


A person with Stage 1 or Stage 2 autoimmune type 1 diabetes does not show any symptoms but type 1 diabetes autoantibodies are already detectable in their blood. During Stage 3, the signs and symptoms of autoimmune type 1 diabetes are already present.2,9

What are the benefits of detecting autoimmune type 1 diabetes early?


Anyone can get an autoantibody screening for type 1 diabetes. The early detection of autoimmune type 1 diabetes through screening has many benefits:

  • Reduces the chance of a medical emergency
  • Allows for tracking autoimmune type 1 diabetes proactively through glucose monitoring
  • Provides more time to prepare for living with autoimmune type 1 diabetes.2,5,14,17


Early diagnosis also provides the opportunity for education and support to people with autoimmune type 1 diabetes and their families, helping them feel as comfortable and informed as possible throughout the progression of the condition.2 On the other hand, screening can provide relief and reassurance if type 1 diabetes autoantibodies are not detected.2


Screening Doctor Discussion Guide

Abbreviations

T1D, type 1 diabetes.

References

1. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi:10.2337/dc15-1419
2. Scheiner G, Weiner S, Kruger DF, Pettus J. Screening for Type 1 Diabetes: Role of the Diabetes Care and Education Specialist. ADCES Pract. 2022;10(5):20-25. doi:10.1177/2633559X221110216
3. Duca LM, Wang B, Rewers M, Rewers A. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. Diabetes Care. 2017;40(9):1249-1255. doi:10.2337/dc17-0558
4. Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2352. doi:10.2337/dc11-1026
5. Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404. doi:10.2337/diacare.27.6.1399
6. Yu L, Zhao Z, Steck AK. T1D Autoantibodies: room for improvement? Curr Opin Endocrinol Diabetes Obes. 2017;24(4):285. doi:10.1097/MED.0000000000000348
7. Wentworth JM, Sing ABE, Naselli G, et al. Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care. 2025;48(4):556-563. doi:10.2337/dc24-2443
8. Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024;67(9):1731-1759. doi:10.1007/s00125-024-06205-5
9. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002
10. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet. 2001;358(9277):221-229. doi:10.1016/S0140-6736(01)05415-0
11. Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760. doi:10.1016/S2213-8587(22)00218-2
12. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. J Pers Med. 2023;13(3):422. doi:10.3390/jpm13030422
13. Sims EK, Besser REJ, Dayan C, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022;71(4):610-623. doi:10.2337/dbi20-0054
14. Ghalwash M, Dunne JL, Lundgren M, et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2022;10(8):589-596. doi:10.1016/S2213-8587(22)00141-3
15. Simmons KMW, Frohnert BI, O’Donnell HK, et al. Historical Insights and Current Perspectives on the Diagnosis and Management of Presymptomatic Type 1 Diabetes. Diabetes Technol Ther. 2023;25(11):790-799. doi:10.1089/dia.2023.0276
16. Phillip M, Achenbach P, Addala A, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care. 2024;47(8):1276–1298. doi:10.2337/dci24-0042
17. Simmons KM and Sims EK. Screening and prevention of type 1 diabetes: Where are we? J Clin Endocrinol Metab. 2023;108(12):3067-3079. doi:10.1210/clinem/dgad328

MAT-GLB-2505731-v1.0-10/25